Oaktree Acquisition Corp. III Life Sciences extended its combination deadline to November 25, 2026, after holders of 11,331,102 public shares redeemed them for an aggregate $122,435,287, leaving an approximately $85.0 million trust balance and substantial doubt about going concern.
OACCU · Oaktree Acquisition Corp. III Life Sciences · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Such potential liquidity shortfalls and mandatory liquidation condition raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Oaktree Acquisition Corp. III Life Sciences shareholders approved extending its deadline from October 25, 2026 to November 25, 2026, with monthly extensions to May 25, 2027. Holders of 11,331,102 public shares redeemed them for approximately $122,435,287.
Oaktree Acquisition Corp. III Life Sciences postponed its extraordinary general meeting from October 16, 2026 to October 23, 2026 to permit further solicitation and vote of proxies on extending the date to complete an initial business combination.
Oaktree Acquisition Corp. III Life Sciences postponed its shareholder General Meeting, originally set for October 16, 2026, to October 23, 2026 at 10:00 a.m. Eastern Time to permit further proxy solicitation for the initial business combination extension proposal.
Oaktree Acquisition Corp. III Life Sciences reported 13,326,977 Class A shares tendered by the October 14, 2026 redemption deadline; conversion of 4,798,758 Class B shares into Class A shares would leave 11,254,791 Class A and 1,000 Class B shares outstanding.
Oaktree Acquisition Corp. III Life Sciences reported 13,326,977 Class A ordinary shares tendered for redemption by 5:00 p.m., Eastern Time, on October 14, 2026; assuming redemptions and the Conversion, 11,254,791 Class A ordinary shares and 1,000 Class B ordinary shares will remain outstanding.
Oaktree Acquisition Corp. III Life Sciences shareholders will vote to extend the Business Combination deadline from October 25, 2026 to November 25, 2026, with up to six optional one-month extensions ending no later than May 25, 2027, and to authorize meeting adjournment if needed.
Oaktree Acquisition Corp. III Life Sciences seeks approval to extend its Business Combination deadline from October 25, 2026 to November 25, 2026, with up to six monthly extensions ending no later than May 25, 2027.